196 related articles for article (PubMed ID: 7609065)
1. Cross-protection of mice against a global spectrum of rabies virus variants.
Lodmell DL; Smith JS; Esposito JJ; Ewalt LC
J Virol; 1995 Aug; 69(8):4957-62. PubMed ID: 7609065
[TBL] [Abstract][Full Text] [Related]
2. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
Lodmell DL; Esposito JJ; Ewalt LC
Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
[TBL] [Abstract][Full Text] [Related]
3. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine.
Yusibov V; Hooper DC; Spitsin SV; Fleysh N; Kean RB; Mikheeva T; Deka D; Karasev A; Cox S; Randall J; Koprowski H
Vaccine; 2002 Aug; 20(25-26):3155-64. PubMed ID: 12163267
[TBL] [Abstract][Full Text] [Related]
4. A recombinant human adenovirus vaccine against rabies.
Prevec L; Campbell JB; Christie BS; Belbeck L; Graham FL
J Infect Dis; 1990 Jan; 161(1):27-30. PubMed ID: 2295855
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the protective efficacy between single and combination of recombinant adenoviruses expressing complete and truncated glycoprotein, and nucleoprotein of the pathogenic street rabies virus in mice.
Kim HH; Yang DK; Nah JJ; Song JY; Cho IS
Virol J; 2017 Jun; 14(1):122. PubMed ID: 28646885
[TBL] [Abstract][Full Text] [Related]
6. Protection of non-human primates against rabies with an adenovirus recombinant vaccine.
Xiang ZQ; Greenberg L; Ertl HC; Rupprecht CE
Virology; 2014 Feb; 450-451():243-9. PubMed ID: 24503087
[TBL] [Abstract][Full Text] [Related]
7. Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein.
Sumner JW; Fekadu M; Shaddock JH; Esposito JJ; Bellini WJ
Virology; 1991 Aug; 183(2):703-10. PubMed ID: 1840709
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein.
Fujii H; Takita-Sonoda Y; Mifune K; Hirai K; Nishizono A; Mannen K
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1339-44. PubMed ID: 8207400
[TBL] [Abstract][Full Text] [Related]
9. A rabies virus vectored severe fever with thrombocytopenia syndrome (SFTS) bivalent candidate vaccine confers protective immune responses in mice.
Tian L; Yan L; Zheng W; Lei X; Fu Q; Xue X; Wang X; Xia X; Zheng X
Vet Microbiol; 2021 Jun; 257():109076. PubMed ID: 33957572
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the immunogenicity of two inactivated recombinant rabies viruses overexpressing the glycoprotein.
Navid MT; Li Y; Zhou M; Cui M; Fu ZF; Tang L; Zhao L
Arch Virol; 2016 Oct; 161(10):2863-70. PubMed ID: 27438075
[TBL] [Abstract][Full Text] [Related]
11. An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice.
Xue XH; Zheng XX; Wang HL; Ma JZ; Li L; Gai WW; Wang TC; Yang ST; Xia XZ
Virus Genes; 2014 Jun; 48(3):411-20. PubMed ID: 24535572
[TBL] [Abstract][Full Text] [Related]
12. Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.
Kang H; Qi Y; Wang H; Zheng X; Gao Y; Li N; Yang S; Xia X
Viruses; 2015 Mar; 7(3):1134-52. PubMed ID: 25768031
[TBL] [Abstract][Full Text] [Related]
13. A thermostable messenger RNA based vaccine against rabies.
Stitz L; Vogel A; Schnee M; Voss D; Rauch S; Mutzke T; Ketterer T; Kramps T; Petsch B
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006108. PubMed ID: 29216187
[TBL] [Abstract][Full Text] [Related]
14. [The induction of protective immune response in mice vaccinated by recombinant avian adenovirus CELO expressing glycoprotein G of the rabies virus].
Shmarov MM; Tutykhina IL; Logunov DIu; Verkhovskai LV; Nedosekov VV; Tsybanov SZh; Novikov BV; Narodnitskiĭ BS; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2006; (4):69-71. PubMed ID: 16941876
[TBL] [Abstract][Full Text] [Related]
15. [Antigenic determination of human anti-rabies vaccine against viral street strains common in the wild animal population in Poland].
Seroka D
Med Dosw Mikrobiol; 1994; 46(4):331-47. PubMed ID: 7541494
[TBL] [Abstract][Full Text] [Related]
16. Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination.
Shuai L; Feng N; Wang X; Ge J; Wen Z; Chen W; Qin L; Xia X; Bu Z
Antiviral Res; 2015 Sep; 121():9-15. PubMed ID: 26093157
[TBL] [Abstract][Full Text] [Related]
17. Canine vaccine recipients recognize an immunodominant region of the rabies virus glycoprotein.
Johnson N; Mansfield KL; Fooks AR
J Gen Virol; 2002 Nov; 83(Pt 11):2663-2669. PubMed ID: 12388801
[TBL] [Abstract][Full Text] [Related]
18. Antigenic variants of rabies virus.
Wiktor TJ; Koprowski H
J Exp Med; 1980 Jul; 152(1):99-112. PubMed ID: 6156982
[TBL] [Abstract][Full Text] [Related]
19. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies.
Tims T; Briggs DJ; Davis RD; Moore SM; Xiang Z; Ertl HC; Fu ZF
Vaccine; 2000 Jun; 18(25):2804-7. PubMed ID: 10812222
[TBL] [Abstract][Full Text] [Related]
20. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.
Xiang ZQ; Yang Y; Wilson JM; Ertl HC
Virology; 1996 May; 219(1):220-7. PubMed ID: 8623532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
